Immutep Limited (IMMP) Nasdaq

Cosa può essere?
tu sei più esperto di me sicuramente ma mi domando:

vista la poca liquidità del titolo come si può fare a far passare un ordine del genere in un colpo ?

ci deve essere qualcuno in acquisto per quella quantità perchè se vendi allo scoperto dove la mandi...

non ho mai visto una cosa del genere su IMMP
 
tu sei più esperto di me sicuramente ma mi domando:

vista la poca liquidità del titolo come si può fare a far passare un ordine del genere in un colpo ?

ci deve essere qualcuno in acquisto per quella quantità perchè se vendi allo scoperto dove la mandi...

non ho mai visto una cosa del genere su IMMP
Stavo facendo lo stesso ragionamento, probabilmente uno scambio concordato, sarebbe bello capire cosa c'è dietro
 
comunque io, vista la qualità dei dati che continuano a tirare fuori, non mi preoccupo

sono positivo
 
1 milione di pezzi?? Come dite voi può essere concordato, magari il nuovo responsabile delle relazioni con gli investitori ha trovato qualcuno che ha chiesto un ingresso conveniente?? Può essere?
 
A me sembra una schermata del sito nasdaq.com
 
1 milione di pezzi?? Come dite voi può essere concordato, magari il nuovo responsabile delle relazioni con gli investitori ha trovato qualcuno che ha chiesto un ingresso conveniente?? Può essere?
Se così fosse dovremmo vedere un sec filling
 
Di solito escono a cose fatte mi pare, o sbaglio? Devono dare comunicazione preventiva?
 
Stavo facendo lo stesso ragionamento, probabilmente uno scambio concordato, sarebbe bello capire cosa c'è dietro
Io ho un’ordine parzialmente eseguito da una settimana,ma ancora inserito a 1,73 e ieri non mi hanno dato niente nonostante il minimo dica 1,67. Non so se può essere d’aiuto
 
Io ho un’ordine parzialmente eseguito da una settimana,ma ancora inserito a 1,73 e ieri non mi hanno dato niente nonostante il minimo dica 1,67. Non so se può essere d’aiuto
Se fosse stata una vendita saresti stato servito
Strano cmq, ho cercato nei secflling e tra insider, niente, vediamo se lunedì compare qualcosa , io sarò in vacanza
Ci risentiamo tra una decina di giorni
Verrò a sbirciare le novità 👋
 
Io ho un’ordine parzialmente eseguito da una settimana,ma ancora inserito a 1,73 e ieri non mi hanno dato niente nonostante il minimo dica 1,67. Non so se può essere d’aiuto
Cvd…oggi servito:'(:shit:sperem
 
Pensavo che avvicinandosi all’evento il titolo salisse:mmmm: perlomeno non scende:D
graficamente com’è messo? C’è qualcuno che può indicare?
 

ASX/Media Release​


Immutep Announces Expansion of Triple Combination Therapy in 1st Line Non-Small Cell Lung Cancer​


  • Expanding INSIGHT-003 trial evaluating efti with standard-of-care combination of anti-PD-1 therapy and chemotherapy to 50 patients

  • Expansion based on safety and strong initial efficacy results

  • Data updates expected throughout CY2023 and cost-efficient approach through investigator-initiated trial will further inform options related to 1L NSCLC development

  • Clinical data to date shows efti uniquely positioned to address entire NSCLC patient population through both chemo-free IO-IO and IO-IO-chemo triple combinations
SYDNEY, AUSTRALIA – 30 March 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces it has signed an agreement to expand the INSIGHT-003 trial evaluating the combination of eftilagimod alpha (“efti”), a soluble LAG-3 protein and first-in-class MHC class II agonist, in conjunction with standard-of-care combination of anti-PD-1 therapy and chemotherapy in 1st line nonsmall cell lung cancer (1L NSCLC).
INSIGHT-003 recently reached its initial enrolment target of 20 patients and will now be expanded to 50 patients across multiple sites. This expansion is based on favourable safety and strong initial efficacy results presented at SITC 2022. Additional data from INSIGHT-003 is expected throughout calendar year 2023.
Prof. Dr. Salah-Eddin Al-Batran of the Institute of Clinical Cancer Research IKF and lead investigator noted: “We’re thrilled to expand the trial population for this triple combination therapy, which has demonstrated promising efficacy and safety in 1st line non-small cell lung cancer patients. We have seen the previous findings that are indicative of powerful synergies of efti’s immune system stimulation with anti-PD-(L)1 therapies and separately with chemotherapy across various solid tumors. As we continue to gather clinical data throughout the year, we eagerly anticipate discovering how this synergy translates in the INSIGHT-003 study, which combines all three modalities.”
Initial results from the triple combination of efti, an anti-PD-1 therapy and chemotherapy in patients with 1L NSCLC show that the therapy is well-tolerated and provides promising early signals of therapeutic activity with an ORR of 72.7% and a Disease Control Rate (DCR) of 90.9%. Additionally, 82% of the eleven evaluable patients had a PD-L1 Tumour Proportion Score (TPS) of <50% and this group reported an encouraging 66.7% ORR and 88.9% DCR.
Patients with low to negative PD-L1 expression represent two-thirds of the 1L NSCLC patient population and are less responsive to anti-PD-(L)1 therapy compared to patients with a PD-L1 TPS of ≥50%. Unlike many dual immuno-oncology combinations (IO-IO) that focus solely on high PD-L1 expressing patients, compelling clinical results to date suggest that efti may be uniquely positioned to address the entire NSCLC patient population regardless of PD-L1 expression through chemo-free IO-IO combinations or IO-IO-chemo triple combinations as INSIGHT-003 is evaluating.
In addition to the Company’s late-stage clinical development efforts focused on 1L NSCLC with the combination of efti and anti-PD-1 therapy (IO-IO), the expansion of INSIGHT-003 will further inform planning for registrational studies. Importantly, this multi-center investigator-initiated trial will generate valuable data in a cost-efficient manner.
Immutep CEO, Marc Voigt, said: “We are grateful for the long-standing support of Dr. Al-Batran and the entire team at IKF. Our valuable relationship with this world-class institution has uncovered many positive attributes of efti and continues to help us cost-effectively advance this novel immunotherapy for patients with advanced solid tumours, including 1st line non-small cell lung cancer.”
 
domani mattina

TACTI-002 (Part B) Abstract (#11MO)
Title: Final data from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3) & pembrolizumab 2nd line metastatic NSCLC patients resistant to PD-1/PD-L1 inhibitors
Presentation session: Mini Oral
Presenter: Margarita Majem, MD, PhD, Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau
Lecture Time: 31 March 2023, 08:25-08:30AM

The abstract (#11MO) will be available here on the ELCC 2023 website. The related Mini Oral Presentation with new and updated final data that are not part of the abstract will made available on 31 March 2023 at 08:25AM, CEST and will subsequently be posted on the Posters & Publications section of Immutep’s website.
 

ASX/Media Release​


Immutep Announces Expansion of Triple Combination Therapy in 1st Line Non-Small Cell Lung Cancer​


  • Expanding INSIGHT-003 trial evaluating efti with standard-of-care combination of anti-PD-1 therapy and chemotherapy to 50 patients

  • Expansion based on safety and strong initial efficacy results

  • Data updates expected throughout CY2023 and cost-efficient approach through investigator-initiated trial will further inform options related to 1L NSCLC development

  • Clinical data to date shows efti uniquely positioned to address entire NSCLC patient population through both chemo-free IO-IO and IO-IO-chemo triple combinations
SYDNEY, AUSTRALIA – 30 March 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces it has signed an agreement to expand the INSIGHT-003 trial evaluating the combination of eftilagimod alpha (“efti”), a soluble LAG-3 protein and first-in-class MHC class II agonist, in conjunction with standard-of-care combination of anti-PD-1 therapy and chemotherapy in 1st line nonsmall cell lung cancer (1L NSCLC).
INSIGHT-003 recently reached its initial enrolment target of 20 patients and will now be expanded to 50 patients across multiple sites. This expansion is based on favourable safety and strong initial efficacy results presented at SITC 2022. Additional data from INSIGHT-003 is expected throughout calendar year 2023.
Prof. Dr. Salah-Eddin Al-Batran of the Institute of Clinical Cancer Research IKF and lead investigator noted: “We’re thrilled to expand the trial population for this triple combination therapy, which has demonstrated promising efficacy and safety in 1st line non-small cell lung cancer patients. We have seen the previous findings that are indicative of powerful synergies of efti’s immune system stimulation with anti-PD-(L)1 therapies and separately with chemotherapy across various solid tumors. As we continue to gather clinical data throughout the year, we eagerly anticipate discovering how this synergy translates in the INSIGHT-003 study, which combines all three modalities.”
Initial results from the triple combination of efti, an anti-PD-1 therapy and chemotherapy in patients with 1L NSCLC show that the therapy is well-tolerated and provides promising early signals of therapeutic activity with an ORR of 72.7% and a Disease Control Rate (DCR) of 90.9%. Additionally, 82% of the eleven evaluable patients had a PD-L1 Tumour Proportion Score (TPS) of <50% and this group reported an encouraging 66.7% ORR and 88.9% DCR.
Patients with low to negative PD-L1 expression represent two-thirds of the 1L NSCLC patient population and are less responsive to anti-PD-(L)1 therapy compared to patients with a PD-L1 TPS of ≥50%. Unlike many dual immuno-oncology combinations (IO-IO) that focus solely on high PD-L1 expressing patients, compelling clinical results to date suggest that efti may be uniquely positioned to address the entire NSCLC patient population regardless of PD-L1 expression through chemo-free IO-IO combinations or IO-IO-chemo triple combinations as INSIGHT-003 is evaluating.
In addition to the Company’s late-stage clinical development efforts focused on 1L NSCLC with the combination of efti and anti-PD-1 therapy (IO-IO), the expansion of INSIGHT-003 will further inform planning for registrational studies. Importantly, this multi-center investigator-initiated trial will generate valuable data in a cost-efficient manner.
Immutep CEO, Marc Voigt, said: “We are grateful for the long-standing support of Dr. Al-Batran and the entire team at IKF. Our valuable relationship with this world-class institution has uncovered many positive attributes of efti and continues to help us cost-effectively advance this novel immunotherapy for patients with advanced solid tumours, including 1st line non-small cell lung cancer.”
nessuna reazione. Non vorrei che hanno provato a buttare becchime per pasturare un po’ di pesci prima di tirare la rete domattina con dei dati non convincenti:mmmm::rolleyes:
 
AIMM.PNG
 
Indietro